Panatus forte, 50 mg 10 pcs

Whooping cough, Cough, Cold, Preparation for bronchoscopy

Dry cough of any etiology, including whooping cough, to suppress cough in pre- and postoperative period, during surgery and bronchoscopy.

Active ingredient

Butamirate

Composition

1 film-coated tablet contains:

Active substance:

Butamirate citrate 50.00 mg

Auxiliaries: lactose monohydrate, povidone K-25, hypromellose 15000 mPas, talc, magnesium stearate, colloidal silicon dioxide

Film coating:hypromellose 6 mPas, titanium dioxide (E171), iron oxide red dye (E172), talc, propylene glycol

How to take, the dosage

Internal, before meals.

Children above 12 years of age: one tablet 1-2 times a day; adults: one tablet 2-3 times a day.

If cough persists more than 5-7 days, you should see a doctor.

Interaction

No drug interactions are described for butamirate.

Because butamirate suppresses the cough reflex, concurrent use of expectorants should be avoided to avoid sputum build-up in the airways.

During the use of Panatus^® forte the use of ethanol as well as CNS depressant drugs (hypnotics, neuroleptics, tranquilizers, etc.) is not recommended.

Special Instructions

Pregnancy (II-III trimesters).

It is contraindicated in children under 12 years of age.

It is contraindicated in patients with lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome.

One film-coated tablet contains 285 mg of lactose. The patient takes up to 285 mg of lactose each time the drug is taken according to the instructions for use. Panatus^® forte is not used in patients with lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome. If after 5-7 days of using Panatus^® forte cough does not stop, consult a physician.

Panatus^® forte may cause drowsiness; therefore, caution should be exercised when driving vehicles and operating complex technical devices that require increased concentration and rapid psychomotor reactions.

Synopsis

Round, biconvex, beveled, film-coated, red-brown tablets.

Fracture appearance: white, rough mass with a red-brown film coating.

Contraindications

High sensitivity to the ingredients of the drug, pregnancy (I trimester), breastfeeding, children under 12 years of age, lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome.

Side effects

World Health Organization (WHO) classification of side effect frequency:

very frequently ≥1/10

often ≥ 1/100 to < 1/10

infrequently from ≥ 1/1000 to < 1/100

rarely from ≥ 1/10000 to < 1/1000

very rarely from ≥ 1/100000, including individual posts.

From the central nervous system (CNS):

rarely: drowsiness, dizziness.

From the digestive system:

rarely: nausea, vomiting, diarrhea.

Skin side:

rarely: exanthema.

Others:possible development of allergic reactions.

Overdose

Symptoms:drowsiness, dizziness, nausea, vomiting, abdominal pain, diarrhea, irritability, impaired coordination of movements, decreased blood pressure.

Treatment:wash the stomach, prescribe activated charcoal, laxatives, and also carry out measures to maintain cardiovascular and respiratory function. There is no antidote. Treatment is symptomatic.

Pregnancy use

There are no data on the safety of the drug Panatus^® forte during pregnancy and its passage through the placental barrier. The drug is not recommended to use in the first trimester of pregnancy. In II and III trimesters of pregnancy the drug may be used only after consultation with a physician. Taking into account the absence of data about excretion of butamirate in maternal milk, it is not recommended to use Panatus® forte during breast feeding.